BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A

INTRODUCTION: Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies. Breast cancer 1 gene (BRCA1)-deficient tumors are usually of the basal subtype and associated with poor survival rates, highlighting the n...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Puppe, Julian, Drost, Rinske, Liu, Xiaoling, Joosse, Simon A, Evers, Bastiaan, Cornelissen-Steijger, Paulien, Nederlof, Petra, Yu, Qiang, Jonkers, Jos, van Lohuizen, Maarten, Pietersen, Alexandra M
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2009
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2750125/
https://ncbi.nlm.nih.gov/pubmed/19709408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2354
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky